PMC:7784786 / 16529-18065 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"585","span":{"begin":98,"end":102},"obj":"Gene"},{"id":"586","span":{"begin":204,"end":208},"obj":"Gene"},{"id":"587","span":{"begin":58,"end":66},"obj":"Species"},{"id":"588","span":{"begin":181,"end":189},"obj":"Species"},{"id":"589","span":{"begin":68,"end":78},"obj":"Chemical"},{"id":"590","span":{"begin":128,"end":138},"obj":"Chemical"},{"id":"591","span":{"begin":43,"end":57},"obj":"Disease"},{"id":"592","span":{"begin":441,"end":450},"obj":"Disease"},{"id":"593","span":{"begin":467,"end":475},"obj":"Disease"},{"id":"596","span":{"begin":636,"end":655},"obj":"Disease"},{"id":"597","span":{"begin":657,"end":665},"obj":"Disease"},{"id":"601","span":{"begin":820,"end":823},"obj":"Gene"},{"id":"602","span":{"begin":814,"end":819},"obj":"Species"},{"id":"603","span":{"begin":752,"end":762},"obj":"Chemical"},{"id":"607","span":{"begin":928,"end":936},"obj":"Disease"},{"id":"608","span":{"begin":964,"end":984},"obj":"Disease"},{"id":"609","span":{"begin":999,"end":1032},"obj":"Disease"},{"id":"612","span":{"begin":1038,"end":1046},"obj":"Species"},{"id":"613","span":{"begin":1065,"end":1075},"obj":"Chemical"},{"id":"618","span":{"begin":1142,"end":1146},"obj":"Gene"},{"id":"619","span":{"begin":1184,"end":1192},"obj":"Species"},{"id":"620","span":{"begin":1111,"end":1121},"obj":"Chemical"},{"id":"621","span":{"begin":1175,"end":1183},"obj":"Disease"},{"id":"623","span":{"begin":1198,"end":1206},"obj":"Species"},{"id":"625","span":{"begin":1287,"end":1297},"obj":"Chemical"},{"id":"628","span":{"begin":1501,"end":1510},"obj":"Disease"},{"id":"629","span":{"begin":1527,"end":1535},"obj":"Disease"}],"attributes":[{"id":"A585","pred":"tao:has_database_id","subj":"585","obj":"Gene:3569"},{"id":"A586","pred":"tao:has_database_id","subj":"586","obj":"Gene:3569"},{"id":"A587","pred":"tao:has_database_id","subj":"587","obj":"Tax:9606"},{"id":"A588","pred":"tao:has_database_id","subj":"588","obj":"Tax:9606"},{"id":"A589","pred":"tao:has_database_id","subj":"589","obj":"MESH:C000597346"},{"id":"A590","pred":"tao:has_database_id","subj":"590","obj":"MESH:C000597346"},{"id":"A591","pred":"tao:has_database_id","subj":"591","obj":"MESH:D016638"},{"id":"A592","pred":"tao:has_database_id","subj":"592","obj":"MESH:D003643"},{"id":"A593","pred":"tao:has_database_id","subj":"593","obj":"MESH:C000657245"},{"id":"A596","pred":"tao:has_database_id","subj":"596","obj":"MESH:D018352"},{"id":"A597","pred":"tao:has_database_id","subj":"597","obj":"MESH:C000657245"},{"id":"A601","pred":"tao:has_database_id","subj":"601","obj":"Gene:923"},{"id":"A602","pred":"tao:has_database_id","subj":"602","obj":"Tax:9606"},{"id":"A603","pred":"tao:has_database_id","subj":"603","obj":"MESH:C000597346"},{"id":"A607","pred":"tao:has_database_id","subj":"607","obj":"MESH:C000657245"},{"id":"A608","pred":"tao:has_database_id","subj":"608","obj":"MESH:D012128"},{"id":"A612","pred":"tao:has_database_id","subj":"612","obj":"Tax:9606"},{"id":"A613","pred":"tao:has_database_id","subj":"613","obj":"MESH:C000597346"},{"id":"A618","pred":"tao:has_database_id","subj":"618","obj":"Gene:3569"},{"id":"A619","pred":"tao:has_database_id","subj":"619","obj":"Tax:9606"},{"id":"A620","pred":"tao:has_database_id","subj":"620","obj":"MESH:C000597346"},{"id":"A621","pred":"tao:has_database_id","subj":"621","obj":"MESH:C000657245"},{"id":"A623","pred":"tao:has_database_id","subj":"623","obj":"Tax:9606"},{"id":"A625","pred":"tao:has_database_id","subj":"625","obj":"MESH:C000597346"},{"id":"A628","pred":"tao:has_database_id","subj":"628","obj":"MESH:D003643"},{"id":"A629","pred":"tao:has_database_id","subj":"629","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Conclusion\nIn summary, in these severe and critically ill patients, itolizumab was able to reduce IL-6 concentrations. Notably, itolizumab-related adverse events were not reported. Patients with baseline IL-6 levels below 200 pg/ml, showed prompt clinical and radiological recovery. We anticipate that the timely use of this anti-inflammatory antibody in combination with the appropriate antiviral and anticoagulant therapy could reduce the mortality associated with COVID-19. The analysis of the complete-series will be published shortly.\nSummary points\nInflammatory cytokine-release syndrome is associated with the progression of the coronavirus disease (COVID-19).\nNo current therapy has proven effective for the management of this syndrome so far.\nItolizumab is a humanized monoclonal antibody that recognizes human CD6 and its effect is associated with the reduction of pro-inflammatory cytokines release.\nWe present three COVID-19 cases who developed severe respiratory distress together with multifocal interstitial pneumonia.\nThe patients were treated with itolizumab combined with antiviral therapies.\nItolizumab reduced circulating IL-6 concentrations in the three COVID-19 patients.\nTwo patients showed rapid ventilatory and radiological improvement and were fully recovered.\nItolizumab-related adverse events were not reported.\nThese cases show that the timely use of this anti-inflammatory antibody in combination with the appropriate antiviral and anticoagulant therapy could reduce the mortality associated with COVID-19."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T55","span":{"begin":568,"end":593},"obj":"Phenotype"},{"id":"T56","span":{"begin":964,"end":984},"obj":"Phenotype"},{"id":"T57","span":{"begin":1023,"end":1032},"obj":"Phenotype"}],"attributes":[{"id":"A55","pred":"hp_id","subj":"T55","obj":"http://purl.obolibrary.org/obo/HP_0033041"},{"id":"A56","pred":"hp_id","subj":"T56","obj":"http://purl.obolibrary.org/obo/HP_0002098"},{"id":"A57","pred":"hp_id","subj":"T57","obj":"http://purl.obolibrary.org/obo/HP_0002090"}],"text":"Conclusion\nIn summary, in these severe and critically ill patients, itolizumab was able to reduce IL-6 concentrations. Notably, itolizumab-related adverse events were not reported. Patients with baseline IL-6 levels below 200 pg/ml, showed prompt clinical and radiological recovery. We anticipate that the timely use of this anti-inflammatory antibody in combination with the appropriate antiviral and anticoagulant therapy could reduce the mortality associated with COVID-19. The analysis of the complete-series will be published shortly.\nSummary points\nInflammatory cytokine-release syndrome is associated with the progression of the coronavirus disease (COVID-19).\nNo current therapy has proven effective for the management of this syndrome so far.\nItolizumab is a humanized monoclonal antibody that recognizes human CD6 and its effect is associated with the reduction of pro-inflammatory cytokines release.\nWe present three COVID-19 cases who developed severe respiratory distress together with multifocal interstitial pneumonia.\nThe patients were treated with itolizumab combined with antiviral therapies.\nItolizumab reduced circulating IL-6 concentrations in the three COVID-19 patients.\nTwo patients showed rapid ventilatory and radiological improvement and were fully recovered.\nItolizumab-related adverse events were not reported.\nThese cases show that the timely use of this anti-inflammatory antibody in combination with the appropriate antiviral and anticoagulant therapy could reduce the mortality associated with COVID-19."}

{"project":"LitCovid-sentences","denotations":[{"id":"T145","span":{"begin":0,"end":10},"obj":"Sentence"},{"id":"T146","span":{"begin":11,"end":118},"obj":"Sentence"},{"id":"T147","span":{"begin":119,"end":180},"obj":"Sentence"},{"id":"T148","span":{"begin":181,"end":282},"obj":"Sentence"},{"id":"T149","span":{"begin":283,"end":476},"obj":"Sentence"},{"id":"T150","span":{"begin":477,"end":539},"obj":"Sentence"},{"id":"T151","span":{"begin":540,"end":554},"obj":"Sentence"},{"id":"T152","span":{"begin":555,"end":667},"obj":"Sentence"},{"id":"T153","span":{"begin":668,"end":751},"obj":"Sentence"},{"id":"T154","span":{"begin":752,"end":910},"obj":"Sentence"},{"id":"T155","span":{"begin":911,"end":1033},"obj":"Sentence"},{"id":"T156","span":{"begin":1034,"end":1110},"obj":"Sentence"},{"id":"T157","span":{"begin":1111,"end":1193},"obj":"Sentence"},{"id":"T158","span":{"begin":1194,"end":1286},"obj":"Sentence"},{"id":"T159","span":{"begin":1287,"end":1339},"obj":"Sentence"},{"id":"T160","span":{"begin":1340,"end":1536},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Conclusion\nIn summary, in these severe and critically ill patients, itolizumab was able to reduce IL-6 concentrations. Notably, itolizumab-related adverse events were not reported. Patients with baseline IL-6 levels below 200 pg/ml, showed prompt clinical and radiological recovery. We anticipate that the timely use of this anti-inflammatory antibody in combination with the appropriate antiviral and anticoagulant therapy could reduce the mortality associated with COVID-19. The analysis of the complete-series will be published shortly.\nSummary points\nInflammatory cytokine-release syndrome is associated with the progression of the coronavirus disease (COVID-19).\nNo current therapy has proven effective for the management of this syndrome so far.\nItolizumab is a humanized monoclonal antibody that recognizes human CD6 and its effect is associated with the reduction of pro-inflammatory cytokines release.\nWe present three COVID-19 cases who developed severe respiratory distress together with multifocal interstitial pneumonia.\nThe patients were treated with itolizumab combined with antiviral therapies.\nItolizumab reduced circulating IL-6 concentrations in the three COVID-19 patients.\nTwo patients showed rapid ventilatory and radiological improvement and were fully recovered.\nItolizumab-related adverse events were not reported.\nThese cases show that the timely use of this anti-inflammatory antibody in combination with the appropriate antiviral and anticoagulant therapy could reduce the mortality associated with COVID-19."}